Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
-
-
-
Apr 15, 2013 Drugs effective against tumors, studies show Tags: aacr 2013, bind-014, daniel von hoff, scottsdale healthcare, tgen
Precision Antibody to develop monoclonal antibodies for NCI
Tags: arizona state university, biodesign institute, proteomics[Source: GenomeWeb News] – Precision Antibody said today that it will develop monoclonal antibodies for 20 cancer-related target proteins for a National Cancer Institute program, under an agreement with NCI contractor SAIC-Frederick.
The company will create the standardized, renewable antibodies for the NCI's Clinical Proteomic Technologies for Cancer (CPTC) project, which is focused on increasing the number of monoclonal antibody reagents that are available for clinical cancer proteomics research.
The CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research, Columbia, Md.-based Precision Antibody said in a statement.
For more information: Precision Antibody to Develop Monoclonal Antibodies for NCI
Quick Links
![]()
“A Bridge Crossed,” a brochure featuring the 2012 progress of Arizona’s Bioscience Roadmap, as well as "Performance Assessment 2002-12," featuring the latest bioscience sector data from Battelle Technology Partnership Practice, are now available.


Share on Twitter
Share on Facebook


